<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02886962</url>
  </required_header>
  <id_info>
    <org_study_id>6396</org_study_id>
    <nct_id>NCT02886962</nct_id>
  </id_info>
  <brief_title>Oral Anticoagulation in Haemodialysis Patients</brief_title>
  <acronym>AVKDIAL</acronym>
  <official_title>Study of the Benefit / Risk Ratio of Oral Anticoagulation in Hemodialysis Patients With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Guidelines recommend oral anticoagulation with vitamin K antagonists for atrial fibrillation
      whenever the CHADS2VASC score is superior or equal to 2. As there are no specific guidelines
      for the hemodialysis patients with atrial fibrillation, the general guidelines apply.
      However, several retrospective studies suggest that these patients do not benefit from the
      oral anticoagulation regarding the risk of stroke and may even experience more bleedings and
      deaths.

      The aim of this prospective study is to prospectively compare the hemorrhagic and thrombotic
      risks of oral anticoagulation in comparison with no anticoagulation in hemodialysis patients
      with atrial fibrillation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2017</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of severe bleedings and thrombosis of oral anticoagulation versus no anticoagulation in hemodialysis patients with atrial fibrillation</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">855</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <arm_group>
    <arm_group_label>No anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No oral anticoagulation, and no monitoring of the INR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral anticoagulation with vitamin K antagonists</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VKA use as recommended in the guidelines with INR target range between 2 and 3. Daily administration or thrice weekly at the end of dialysis sessions upon Nephrologist's choice.
Antiplatelet therapy will be provided only if recent acute coronary syndrome (&lt; 6 months) or active coronary stent. Aspirin should be preferred in dialysis patients as clopidogrel has an unpredictable reduced activity and there is no safety data on combination of VKA with prasugrel or ticagrelor in this population.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>No oral anticoagulation</intervention_name>
    <description>No oral anticoagulation, and no monitoring of the INR.</description>
    <arm_group_label>No anticoagulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral anticoagulation with vitamin K antagonists</intervention_name>
    <description>Vitamin K antagonist prescription with INR target between 2 and 3 as recommended in the guidelines.
Administration once daily or at the end of each dialysis session, according to the nephrologist choice.
INR monitoring at least once per week</description>
    <arm_group_label>Oral anticoagulation with vitamin K antagonists</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (≥ 18 years)

          -  Patient on hemodialysis treatment for at least 1 month

          -  Patient with a history of, or presenting a new episode of atrial fibrillation (either
             permanent or paroxysmal).

          -  Patient with a CHADS2VASC score ≥2

          -  Patient with high risk of bleeding as defined by (1) HASBLED score ≥3 OR (2) HASBLED ≥
             CHADS2VASC score, OR (3) recent history of severe bleeding (type 3a, 3b, 3c),
             particularly cerebral or gastrointestinal, OR (4) prior recurrent (&gt;2) history of
             falls.

          -  Patient capable of understanding information about the study and of giving his/her
             consent

          -  Patient informed of the preliminary medical exam results

          -  Patient with healthcare insurance

          -  Written consent signed

        Exclusion Criteria:

          -  Formal indication to oral anticoagulation beside atrial fibrillation (mechanic heart
             valves, recurrent thrombophlebitis, antiphospholipid syndrome)

          -  Life expectancy &lt; 6 months (e.g., terminal cancer)

          -  Live donor transplantation scheduled within 6 months

          -  Pregnancy (β-HCG blood-based assay)or nursing (lactating) women

          -  Women of child bearing potential, unless they are using an effective method of birth
             control

          -  Patient under legal guardianship

          -  Patients under law protection

          -  Known hypersensibility to coumadin or indoine derivatives or to any excipients (CI to
             oral AVK)

          -  Severe liver failure (CI to oral AVK)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thierry Hannedouche, MD</last_name>
    <phone>0388116768</phone>
    <email>thierry.hannedouche@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thierry Krummel, MD</last_name>
    <phone>0388116768</phone>
    <email>thierry.krummel@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Néphrologie et médecine interne</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabriel CHOUKROUN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU d'Angers - Service de Néphrologie</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Virginie Besson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service Néphrologie, Dialyse, Transplantation</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick HENRI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pathologie Rénale</name>
      <address>
        <city>Chambéry</city>
        <zip>73000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laure Croze, MD</last_name>
      <phone>0479965084</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Néphrologie</name>
      <address>
        <city>Cherbourg-Octeville</city>
        <zip>50102</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume QUEFFEULOU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de néphrologie</name>
      <address>
        <city>Colmar</city>
        <zip>68000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandre KLEIN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de néphrologie</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emmanuelle KOHLER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aurad Aquitaine</name>
      <address>
        <city>Gradignan</city>
        <zip>33170</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine LASSEUR, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Haguenau - service de Néphrologie</name>
      <address>
        <city>Haguenau</city>
        <zip>67504</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yves DIMITROV, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Bouchard</name>
      <address>
        <city>Marseille</city>
        <zip>13006</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jérome SAMPOL, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Néphrologie</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luc Frimat, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ECHO de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angelo TESTA, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Néphrologie</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frédéric LAVAINNE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AURA Paris Plaisance</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maxime TOUZOT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon - Service de Néphrologie</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hafedh FESSI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de néphrologie</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cécile VIGNEAU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NéphroCare Tassin-Charcot</name>
      <address>
        <city>Saint-foy-les-lyon</city>
        <zip>69110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume JEAN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ECHO CA Laennec</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44821</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dan HRISTEA, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Néphrologie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Hannedouche, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Bretagne-Atlantique</name>
      <address>
        <city>Vannes</city>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre Yves DURAND, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Calydial CH Lucien Hussel</name>
      <address>
        <city>Vienne</city>
        <zip>38209</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Agnès CAILLETTE BEAUDOIN, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2016</study_first_submitted>
  <study_first_submitted_qc>August 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2016</study_first_posted>
  <last_update_submitted>September 7, 2017</last_update_submitted>
  <last_update_submitted_qc>September 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin K</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

